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Introduction: Exercise limitation and exertional dyspnea are important symptoms of
chronic obstructive pulmonary disease (COPD), which may be partially relieved by
tiotropium. Although the mechanism of relief is multifactorial, improved dynamic
ventilatory mechanics appear to be important. It is not however known whether
tiotropium may also act by improving cardiovascular function during exercise.
Methods: We conducted a randomized, placebo-controlled crossover study in 18 COPD
subjects with a FEV1 4073% predicted (mean7SEM). Subjects inhaled either tiotropium
18 mg or placebo once daily for 7–10 days then the other intervention for a further 7–10
days after a 35-day washout period. Subjects performed constant work rate cycle exercise
at 75% of maximum after each treatment period. Heart rate, blood pressure, oxygen
uptake, operating lung volumes and breathing pattern were measured.
Results: Heart rate was 7 beats/min lower at rest and throughout exercise with
tiotropium compared to placebo (p ¼ 0.001). Oxygen uptake was unchanged throughout
exercise. Oxygen pulse on exercise was greater by 7.4% (po0.01) and systolic blood
pressure was lower by 7mmHg (p ¼ 0.03). The cardiac rate pressure product was reduced
by 7.6% (po0.01) with tiotropium. Exercise endurance tended to be greater with
tiotropium. Reduction in heart rate on exercise correlated with an increase in inspiratory
reserve volume (r ¼ 0.50, p ¼ 0.04).
Conclusion: Tiotropium may improve cardiac as well as pulmonary function during
exercise in COPD. We suggest that this effect may be due, in part, to improved
cardiopulmonary interaction as a result of mechanical unloading of the ventilatory muscles
however further study is required. ClinicalTrials.gov Identiﬁer: NCT00274027.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
5482342; fax: +1 613 5491459.
ensu.ca (D.E. O’Donnell).
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Exercise limitation and exertional dyspnea are often the
most important symptoms experienced by individuals with
chronic obstructive pulmonary disease (COPD). The cause of
exercise limitation is multifactorial. Dynamic pulmonary
hyperinﬂation during exercise with resulting neuromechani-
cal dissociation is likely to be important in individuals
with moderate to severe COPD.1 Abnormalities of cardio-
vascular function, pulmonary gas exchange, peripheral
muscle function, and perception of symptoms may also
contribute.2–4
Tiotropium bromide is a long acting anticholinergic agent
that has demonstrated efﬁcacy as inhaled therapy for COPD
in improving exertional dyspnea, health status, spirometry,
exercise tolerance and exacerbation frequency.5–7 It is as
effective or more effective than the short acting antic-
holinergic agent ipratropium and the long-acting b-adrenor-
eceptor agonist salmeterol.8,9 Tiotropium therapy produces
a reduction in dynamic hyperinﬂation and neuromechanical
dissociation during exercise in COPD patients,10 a potential
explanation for the improvements in exertional dyspnea and
exercise capacity.
What is not known is whether the beneﬁcial effect of
tiotropium on exercise capacity may be due in part to
improvements in the cardiovascular response to exercise. No
study to date has examined the cardiovascular effects of
tiotropium during exercise. Tiotropium could affect the
cardiovascular system either directly or through its pulmon-
ary effects via a cardiopulmonary interaction. A direct
cardiac action is plausible as other anticholinergic agents
are known to exert direct effects on the cardiovascular
system. Atropine is a nonselective anticholinergic that
increases heart rate and myocardial work at rest and during
exercise.11 In contrast, when the anticholinergic agents
ipratropium and oxitropium are inhaled, resting heart rate
may be slightly reduced.12,13 Oxitropium has also been
shown to slightly attenuate the exercise-induced rise in
pulmonary artery pressure in COPD patients.13 Like ipra-
tropium and oxitropium, tiotropium has not been associated
with classic anticholinergic effects such as tachycardia and
may also slightly reduce resting heart rate.14 Tiotropium
however differs from traditional anticholinergic agents in its
relative kinetic selectivity for M1 and M3 airway muscarinic
receptor subtypes over the M2 cardiac muscarinic receptor
subtype15 and its direct cardiac effects during exercise are
unknown.
Another possibility is that tiotropium may affect the
cardiovascular response to exercise by improving expiratory
airﬂow and pulmonary mechanics via a cardiopulmonary
interaction. Tiotropium improves dynamic hyperinﬂation
during exercise.7,16 This allows tidal breathing to occur on
the more favorable, linear portion of the respiratory
pressure–volume curve and allows tidal breaths to be
generated using less negative inspiratory pleural pres-
sures.10 Negative pleural pressures increase cardiac after-
load as the ventricles must overcome the transmural
pressure, the difference between thoracic and ventricular
pressure, in addition to arterial pressure.17,18 This cardio-
pulmonary interaction may be a limiting factor for exercise
in individuals with severe COPD19 and other cardiopulmon-
ary interactions may also be relevant.We recently conducted a controlled clinical study
designed to assess the effect of tiotropium on the sensory
and pulmonary responses to exercise in COPD patients.10 In
the current study, we assessed cardiovascular data obtained
at the time of this study to determine the effect of
tiotropium on the cardiovascular response to exercise in
COPD.
Methods
Subjects
Subjects were eligible for inclusion if they had COPD,20 were
clinically stable, had a X20 pack-year cigarette smoke
exposure, a forced expiratory volume in 1 s (FEV1) p65%
predicted, a functional residual capacity (FRC) X120%
predicted and a modiﬁed baseline dyspnea index score
p6.21 Subjects were excluded if they had comorbid disease
that could contribute to dyspnea and exercise limitation, a
contraindication to exercise testing,22 daytime oxygen use
or had participated in a pulmonary rehabilitation program in
the 6 weeks prior to the study.
Study design
The study incorporated a randomized, double-blind, place-
bo-controlled crossover design. Approval was obtained from
the local hospital and university research ethics board. After
giving written informed consent, subjects completed a
screening assessment to determine eligibility where medical
history, physical examination, chronic dyspnea evaluation,
pulmonary function testing and a symptom-limited incre-
mental cycle exercise test were performed. Eligible subjects
entered a baseline period during which further pulmonary
function tests and a constant load exercise test were
performed to familiarize subjects with testing procedures
in order to avoid possible learning effects. These tests were
performed again both prior to and at the end of each of two
7–10 day treatment periods separated by a 35 day washout
period. During each treatment period, subjects inhaled
visually identical study medication, either tiotropium 18 mg
or placebo, once daily in addition to other regular
medication. Subjects were randomized in blocks of four
using commercial software (ClinPro/LBLVersion 5.2, Clinical
Systems Inc.) to have an equal chance of being allocated to
receive tiotropium during the ﬁrst treatment period
followed by placebo during the second treatment period or
placebo during the ﬁrst treatment period followed by
tiotropium during the second treatment period. Subjects
completed a follow up visit 1 week after completion of the
second treatment period consisting of a physical examina-
tion and pulmonary function tests.
Subjects avoided oral and long-acting b-agonists for 1
week before the screening visit and throughout the study
and short-acting anticholinergics for 1 day before and
throughout the study. Tiotropium or other long-acting
anticholinergics were avoided apart from the study medica-
tion. Salbutamol was provided as an aerosol inhaler as
rescue medication during the study. Concomitant regular
corticosteroids and theophylline were permitted throughout
the study except that before each study visit, short-acting
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at least 24 and 48 h, respectively. Subjects avoided b-agonist
use, caffeine, alcohol, heavy meals and major physical
exertion before study visits which were all held in the
morning. Post treatment assessments were performed
80–120min after the last study medication dose.
Procedures
Pulmonary function measurements were collected according
to recommended standards23–25 by use of automated
equipment (Vmax 229d with Autobox 6200 DL, SensorMedics,
Yorba Linda, CA) and expressed as percentages of predicted
normal values as previously described.10 Predicted inspira-
tory capacity (IC) was calculated as predicted total lung
capacity (TLC) minus predicted FRC. Symptom-limited
exercise tests were conducted on an electronically braked
cycle ergometer (Ergometrics800S, SensorMedics) by use of
a cardiopulmonary exercise testing system (Vmax 229d,
SensorMedics) as previously described.7,26–28 Incremental
exercise testing was performed using 1min increments of
10W each following a 1min warm up of unloaded pedaling.
Constant-load tests were performed at 75% of the maximal
incremental work rate for each subject. Endurance time was
deﬁned as the duration of loaded pedaling.
Measurements were collected while subjects breathed
through a mouthpiece with a low-resistance ﬂow transducer
while nose clips were worn. Standard cardiopulmonary
exercise test parameters29 were collected on a breath-by-
breath basis. Intensity of dyspnea and leg discomfort was
recorded using the 10-point Borg scale30 at rest, during the
last 30 s period of every 1min interval during exercise and at
end exercise. Operating lung volumes were derived from IC
manoeuvres1,28 performed at rest, within the last 30 s period
of every 2min interval during exercise and at end exercise.
Blood pressure was measured by auscultation of the right
brachial artery, using a sphygmomanometer with an arm
cuff, at rest, within the ﬁrst 30 s period of every 2min
interval, at end exercise and every 5min during recovery
until blood pressure measurements returned to near base-
line. Oxyhemoglobin saturation was recorded continuously
via a pulse oximeter.
Analysis of exercise endpoints
All breath-by-breath measurements were averaged in 30 s
intervals throughout each test stage, rest, exercise and
recovery. To avoid contamination of breath-by-breath data
by the artifact of the IC maneuver, symptom ratings and IC
measurements collected in a 30 s period that included an IC
maneuver were linked to breath-by-breath data collected in
the previous 30 s period. Systolic and diastolic blood
pressure measurements were linearly extrapolated where
necessary to give an estimated blood pressure that was
linked to breath-by-breath data and symptom ratings
obtained in between blood pressure measurements. Pre-
exercise rest was deﬁned as the steady-state period after at
least 3min of quiet breathing on the mouthpiece while
seated at rest before exercise. Cardiopulmonary parameters
were averaged over the last 30 s of this period and IC
measurements at rest were collected while breathing on thesame system immediately after completion of the quiet
breathing period. A standardized time near end exercise
(isotime) was deﬁned as the highest common exercise time
achieved during post treatment constant-load tests per-
formed by a given subject, rounded down to the nearest
whole minute. Peak exercise was deﬁned as the last 30 s of
loaded pedaling, cardiopulmonary parameters were aver-
aged over this period, symptom ratings and IC measure-
ments were collected immediately at the end of this period.
The rate pressure product, a noninvasive marker of
myocardial oxygen consumption31 was calculated as heart
rate multiplied by systolic blood pressure.
Statistical analysis
The sample size was chosen to have adequate power to
detect a 300ml difference in IC at isotime. po0.05
signiﬁcance level was used for all analyses. Treatment
responses were compared by two-tailed paired t-tests.
Pearson correlations were used to establish associations
between cardiopulmonary variables. Data are shown as
mean plus or minus the standard error of the mean.
Results
Eighteen subjects completed the study (Table 1). No subject
experienced oxyhemoglobin desaturation below 88% or a
signiﬁcant elevation of end-tidal carbon dioxide tension
during incremental exercise. No sequence or carryover
effects were found with respect to cardiovascular variables,
pulmonary variables or symptoms. The work rate for
constant load exercise was 5075W.
Effect of tiotropium at rest
Heart rate was lower at rest following tiotropium treatment
compared to placebo by 6.771.8 beats/min (95% conﬁdence
interval 3.2–10.1, p ¼ 0.001). Diastolic blood pressure and
the rate pressure product were also lower by 4.071.5mmHg
(95% conﬁdence interval 1.0–7.0, p ¼ 0.014) and
9007200mmHg beats/min (95% conﬁdence interval
400–1300, p ¼ 0.001), respectively (Table 2). Other cardi-
ovascular variables were not signiﬁcantly changed. FEV1 and
FVC increased at rest following tiotropium treatment
compared to placebo (Table 2). There was no signiﬁcant
change in the FEV1/FVC ratio. Lung hyperinﬂation and
airway resistance decreased and airway conductance in-
creased with tiotropium. Breathing pattern during preex-
ercise rest was unchanged except that the ratio of
inspiratory time to total breath time increased with
tiotropium (p ¼ 0.003).
Effect of tiotropium on the response to exercise
Post-treatment exercise endurance time was greater by
0.970.8min or 14% after tiotropium compared to placebo,
not a statistically signiﬁcant difference. Selected mean
cardiovascular and pulmonary responses to exercise are
shown in Fig. 1. Heart rate was signiﬁcantly lower with
tiotropium throughout exercise. Oxygen uptake (VO2) was
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Table 1 Subject characteristics.
Study subjects
n ¼ 18
Male gender, % 72
Age, yr 6072
Body mass index, kg/m2 26.871.2
Cigarette smoke exposure, pack-years 5878
Baseline Dyspnea Index Focal score 5.270.3
Symptom limited peak incremental
work rate, W
6577 (41)
Systolic blood pressure, mmHg 12773
Diastolic blood pressure, mmHg 8371
Heart rate, beats/min 7372
FEV1, l 1.1370.09 (40)
FEV1/FVC, % 4472 (62)
FEF50, l/s 0.4570.06 (11)
SVC, l 2.9770.17 (75)
IC, l 1.9470.12 (67)
TLC, l 7.4570.25 (122)
RV, l 4.4870.19 (216)
FRC, l 5.5170.20 (171)
MIP at FRC, cmH2O 6075 (71)
MEP at TLC, cmH2O 108710 (58)
DLCO, mL/min/mmHg 14.271.2 (64)
Values are means7SE (percent of predicted normal values
are given in parentheses).
FEV1, forced expiratory volume in 1 s.
FVC, forced vital capacity.
FEF50, forced expiratory ﬂow at 50% of FVC.
SVC, slow vital capacity.
IC, inspiratory capacity.
TLC, total lung capacity.
RV, residual volume.
FRC, functional residual capacity.
MIP, maximal inspiratory mouth pressure.
MEP, maximal expiratory mouth pressure.
DLCO, diffusing capacity of the lung for carbon monoxide.
Table 2 Post dose resting cardiovascular variables,
pulmonary function and breathing pattern measurements
at the end of each treatment period.
Placebo Tiotropium
Cardiovascular variables
Heart rate,
beats/min
7972 7272*
VO2, l/min 0.3270.02 0.3170.02
Oxygen pulse,
mL/beat
4.1370.32 4.3770.35
Systolic blood
pressure, mmHg
124.472.7 123.673.0
Diastolic blood
pressure, mmHg
82.472.0 78.471.1
Oxyhemoglobin
saturation, %
95.770.3 95.570.3
Rate pressure
product,
mmHg.beats/min
98007400 89007300*
Pulmonary function
FEV1, l 1.1870.10 (42) 1.3870.11 (49)*
FEV1/FVC, % 4472 (62) 4572 (63)
FEF50, l/s 0.5270.07 (53) 0.5770.06 (14)
SVC, l 3.0570.19 (77) 3.3170.20 (84)*
TLC, l 7.3670.17 (121) 7.2770.25 (119)
RV, l 4.3170.23 (208) 3.9770.20 (192)*
FRC, l 5.3870.24 (167) 5.0970.22 (158)*
Steady-state breathing pattern
IC, l 2.0270.12 2.2570.13*
IRV, l 1.3570.13 1.5770.13*
EELV, l 5.3370.23 5.0070.20*
VT, l 0.6870.03 0.6870.04
Respiratory rate,
breaths/min
18.670.9 18.871.0
VT/TI, l/s 0.5870.03 0.5870.03
VT/TE, l/s 0.3570.02 0.3570.02
TI, s 1.2070.06 1.3370.08
TI/Ttot 0.3670.01 0.4070.01*
Values are means7SE (percent of predicted normal values
are given in parentheses). *po0.01 tiotropium versus
placebo.
VO2, oxygen uptake.
FEV1, forced expiratory volume in 1 s.
FVC, forced vital capacity.
FEF50, forced expiratory ﬂow at 50% of FVC.
SVC, slow vital capacity.
TLC, total lung capacity.
RV, residual volume.
FRC, functional residual capacity.
J. Travers et al.2020no different and oxygen pulse tended to be higher with
tiotropium, signiﬁcantly so at isotime and at peak exercise.
Systolic and diastolic blood pressures were lower with
tiotropium at all stages of exercise however the statistical
signiﬁcance of these differences was marginal. The rate
pressure product was signiﬁcantly lower with tiotropium at
rest and at isotime. Inspiratory reserve volume (IRV) was
signiﬁcantly greater at rest and throughout exercise.
Cardiovascular and pulmonary variables at isotime near
peak exercise after tiotropium and placebo treatment are
given in Table 3.IC, inspiratory capacity.
IRV, inspiratory reserve volume.
EELV, end-expiratory lung volume.
VT, tidal volume.
TI, inspiratory time.
TE, expiratory time.
Ttot, total breath time.Correlates of reduced heart rate on exercise
The difference in heart rate at isotime with tiotropium
compared to placebo correlated with the difference in end-
inspiratory lung volume (EILV) as a percent of TLC (partial
multiple r ¼ 0.53, p ¼ 0.02) and the difference in IRV
(partial multiple r ¼ 0.50, p ¼ 0.04) more strongly than
with any other measured cardiopulmonary variables.
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Figure 1 Cardiovascular, IRV and dyspnea response to exercise. Open circles, placebo. Filled circles, tiotropium. Data points are
means of all subjects. *po0.05 tiotropium versus placebo. **po0.01 tiotropium versus placebo. VO2, oxygen uptake, RPP, rate
pressure product, SBP, systolic blood pressure, DBP, diastolic blood pressure, IRV, inspiratory reserve volume.
Cardiovascular effects of tiotropium during exercise 2021Discussion
The novel ﬁnding of this study is a consistent, statistically
signiﬁcant and potentially clinically important effect of
tiotropium on the cardiovascular response to exercise in
subjects with COPD. Heart rate was lower with tiotropium at
rest and throughout exercise by 7 beats/min with a
corresponding increase in oxygen pulse, a surrogate measureof cardiac stroke volume, and a reduction in the rate
pressure product, a surrogate measure of myocardial work
at isotime during exercise. The reduction in heart rate at
isotime during exercise correlated best with indices of
dynamic hyperinﬂation, suggesting an association between
the cardiac effects of tiotropium and improved pulmonary
mechanics. These results suggest that either tiotropium
exerts a direct effect on the cardiovascular system or that
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Table 3 Post dose cardiovascular and pulmonary
measurements at isotime near peak exercise.
Placebo Tiotropium
Heart rate, beats/min 11274 10574*
VO2, l/min 1.1270.10 1.1470.11
Oxygen pulse, mL/beat 10.170.9 10.971.0*
Systolic blood pressure,
mmHg
15676 14875*
Diastolic blood pressure,
mmHg
8872 8571
Oxyhemoglobin saturation, % 94.170.4 93.570.6
Rate pressure product, mmHg
beats/min
173007900 156007900*
VE, l/min 35.873.1 35.473.2
VE/VCO2 34.371.7 34.871.7
Respiratory rate, breaths/min 29.871.6 27.671.2*
VT, l 1.2070.08 1.2670.09
IC, l 1.6370.09 1.8670.13*
IRV, l 0.4470.07 0.6070.11*
EILV, %TLC 9471 9271
Dyspnea, Borg scale 4.470.6 3.670.4
Leg discomfort, Borg scale 4.270.5 4.270.5
Values are means7SE. *po0.05 tiotropium versus placebo.
VO2, oxygen uptake.
VE, minute ventilation.
VCO2, carbon dioxide production.
VT, tidal volume.
IC, inspiratory capacity.
IRV, inspiratory reserve volume.
EILV, end-inspiratory lung volume.
TLC, total lung capacity.
J. Travers et al.2022the bronchodilating and lung deﬂating actions of tiotropium
result in improved cardiac function via a cardiopulmonary
interaction.Potential direct cardiovascular effects of tiotropium
Tiotropium administered by inhalation is mostly swallowed,
very little of which is absorbed systemically.32 The fraction
that reaches the lung has a high bioavailability giving peak
plasma concentrations approximately 60% of that achieved
by intravenous administration and persisting in plasma for
longer.32 Although systemically available, the current results
cannot be explained by tiotropium antagonism at cardiac M2
muscarinic receptors as this effect would produce an
increase rather than a decrease in heart rate. Tiotropium
antagonism of the M3 receptors of the pulmonary vascu-
lature may result in both inhibition of vasoconstriction and
inhibition of endothelial-dependent vasodilatation. It is
possible that the net effect of these actions may reduce
resting or exercise-induced pulmonary vascular tone and
pulmonary arterial pressure.
Studies of the cardiovascular effects of tiotropium at rest
have reported few clinically signiﬁcant effects.33 A recent
meta-analysis34 suggests that there is an increased rate of
cardiac arrhythmias, primarily atrial ﬁbrillation, withtiotropium although this increase was statistically signiﬁcant
only after one study responsible for signiﬁcant heterogene-
ity was excluded. An increased rate of cardiac death with
ipratropium was noted in the Lung Health study35 but this
ﬁnding was not replicated in other studies36 and has not
been reported with tiotropium.
Potential cardiopulmonary interactions
Tiotropium signiﬁcantly improved measures of dynamic
hyperinﬂation during exercise, conﬁrming the ﬁndings of
other studies.7,16 As described above, this effect could
result in reduced cardiac afterload which may explain the
observed improvement in cardiac function. The association
of improvement in EILV and IRV, both measures of dynamic
hyperinﬂation, with improvement in heart rate is consistent
with this hypothesis but the association does not imply
causation. Other potential interactions mediating the effect
of tiotropium include improved pulmonary blood ﬂow
associated with reduced air trapping,13 reduction in heart
rate due to reduced discharge from slowly adapting
pulmonary stretch receptors,37 reduction in left ventricular
compression from right ventricular overﬁlling38 and reduc-
tion in positive pleural pressure during expiration.39
Relation to other research
We are not aware of any other study that has examined the
effect of tiotropium on the cardiovascular response to
exercise. The reduction in heart rate during exercise that
we observed with tiotropium was not seen with either the
short-acting anticholinergic oxitropium or the short-acting
b-agonist fenoterol in a study of exercise hemodynamics.13 A
study of the effects of the long-acting b-agonist salmeterol
during exercise also showed no reduction in heart rate
despite a similar degree of improvement in dynamic
hyperinﬂation to that observed with tiotropium.26 The
apparent difference between tiotropium and salmeterol is
suggestive of a direct cardiovascular effect of tiotropium.
The alternative explanation is that both agents act to
reduce heart rate during exercise via improved cardiopul-
monary interactions but in the case of salmeterol the effect
is obscured by the tachycardia resulting from systemic
b-adrenergic stimulation.
Clinically and statistically signiﬁcant differences in
exercise endurance time with tiotropium have been pre-
viously reported in large trials.7,16 In the present study,
mean exercise endurance time was increased with tiotro-
pium however the study was not powered to detect a
statistically signiﬁcant difference.
Limitations of this study
The data presented here were derived from a study
primarily designed to assess the pulmonary and symptomatic
response to exercise in COPD so a full range of hemodynamic
measurements was not undertaken. Oxygen pulse and rate
pressure product are only surrogate measures of stroke
volume and myocardial work, respectively. We have no
reason to suspect that the changes in these measures
observed with tiotropium do not reﬂect similar changes in
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utilizing invasive hemodynamic measurement is required to
conclusively determine this. Likewise, we were not able to
directly measure cardiac output, ejection fraction or
pulmonary artery pressure to help explain the mechanism
or mechanisms by which tiotropium affects the cardiac
response to exercise and determine whether the effect of
tiotropium on the cardiovascular system is physiologically
beneﬁcial or not. From our data, we observed that exercise
endurance was at least as good with tiotropium while
measures of myocardial work were reduced suggesting that
the effect of tiotropium is more likely to be beneﬁcial than
not. As the current analysis was performed post hoc, the
chance that the results presented here represent a type I
error is increased. The consistency of the effect throughout
exercise suggests that the effect is real however prospective
validation is required.
Conclusion
Tiotropium may improve cardiac as well as pulmonary
function during exercise in COPD. We hypothesize that this
is due to a reduction in negative inspiratory pressure
brought about by alleviation of dynamic hyperinﬂation
through bronchodilation rather than a direct effect of
tiotropium on the heart. Further study is required to
determine the mechanism of this effect.
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